Brought to you by 
Daiichi Sankyo acquires majority of Zenotech for R782.4mm
16 Sep 2010
Executive Summary
A year after postponing an open offer that started in early 2009 for Zenotech Laboratories Inc., Daiichi Sankyo Co. Ltd. has now completed the acquisition of an additional 20% of the public Indian biogeneric firm for R782.4mm ($16.9mm), or R113.62 per share--an 11% premium over Zenotech's average prior to the January 2009 announcement. Daiichi's Ranbaxy Laboratories Ltd. subsidiary now owns 67% of Zenotech.
Deal Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Daiichi Sankyo acquires majority of Zenotech for R782.4mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice